About Vir Biotechnology
Vir Biotechnology is a clinical-stage biopharmaceutical company that leverages the immune system to discover and develop medicines for serious infectious diseases and cancer. Its pipeline includes investigational therapies targeting hepatitis delta virus (HDV), hepatitis B, HIV, and solid tumors, using its proprietary antibody discovery platform, AI-driven dAIsY system, and PRO-XTEN masking technology. Customers are patients and healthcare providers globally, with the company currently generating revenue primarily through licensing rights and grants.
Company details
Funding
Total raised
$908.6M
Last stage
Public
Investors
Founders
Robert Nelsen
Managing Director at ARCH Venture Partners; co-founded Vir Biotechnology and led the firm's $150M seed investment alongside the Bill & Melinda Gates Foundation.
LinkedInKlaus Frueh
Listed as co-founder of Vir Biotechnology by Tracxn; scientific co-founder of the company.
George Scangos
Former CEO of Biogen, recruited as founding CEO of Vir Biotechnology at launch in 2017; led the company through its IPO in 2019 and retired in April 2023.
LinkedInLouis Picker
Scientific co-founder whose viral vector technologies, originally developed at Oregon Health & Science University, formed part of Vir's early technology foundation.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.